MET and small cell lung carcinoma: Resistance mechanisms are highly complex and multifaceted, including the emergence of the C797S mutation, the loss of T790M, small cell lung cancer (SCLC) transformation, and MET amplification; thus, tumor biopsy upon disease progression should be considered whenever feasible to optimize treatment strategies [22,23].